https://www.selleckchem.com/products/nhwd-870.html
The performance of prognostic gene expression profile (GEP) tests for cutaneous melanoma is poorly characterized. To systematically assess the performance of commercially available GEP tests in patients with American Joint Committee on Cancer (AJCC) stage I or stage II disease. For this systematic review and meta-analysis, comprehensive searches of PubMed/MEDLINE, Embase, and Web of Science were conducted on December 12, 2019, for English-language studies of humans without date restrictions. Two reviewers identified GEP external valida
Like
Comment
Share
